该意见中提到的进口税与其乳腺癌药物Enhertu有关。阿斯利康早先估计，由于涉嫌未缴纳另外两种抗 癌药物 Imfinzi 和 Imjudo 的进口税，该公司可能仅被罚款 450 万美元，这让分析师们感到安心。 尽管拥有强大的产品线，但阿斯利康在其最大的两个市场——美国和中国——正面临逆风：在中国的丑 闻、美国可能对医药产品征收关税，以及双方之间的关税。 业绩指引 阿斯利康重申了2025财年的总收入和核心每股收益指导。总收入预计将以较高的个位数百分比增长；核 心每股收益预计将以两位数的百分比增长。 这家英国制药商确认了其今年的业绩预期，并表示在制药业准备应对关税之际，公司致力于在美国投资 和发展。药品未被纳入特朗普政府最近对各种进口产品征收的关税范围。 智通财经APP获悉，阿斯利康(AZN.US)公布的2025年第一季度利润超出预期，并重申其全年业绩指 引。财报显示，阿斯利康一季度总营收135.9亿美元，不及市场预期；核心每股收益为 2.49 美元，同比 增长21%，超过分析师预期。 受肿瘤和生物制药业务两位数增长的推动，阿斯利康一季度总营收同比增长10%（以固定汇率计算）， 达到135.9亿美元。该公司第一季 ...

Core Insights - Quest Diagnostics Incorporated reported better-than-expected first-quarter earnings with earnings of $2.21 per share, surpassing the analyst consensus estimate of $2.15 per share [1] - The company achieved quarterly sales of $2.65 billion, exceeding the analyst consensus estimate of $2.63 billion [1] Financial Performance - In the first quarter, Quest Diagnostics experienced strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, attributed to demand recovery in March [2] - The growth was driven by contributions from acquisitions, large enterprise accounts, demand for advanced diagnostics, and expanded health plan access [2] - The company reaffirmed its 2025 revenue guidance of $10.70 billion to $10.85 billion, compared to the consensus of $10.78 billion, and adjusted EPS guidance of $9.55 to $9.80, against the consensus of $9.68 [2] Stock Performance - Following the earnings announcement, Quest Diagnostics shares fell 0.1% to trade at $172.71 [3] - Analysts adjusted their price targets for Quest Diagnostics after the earnings report [3] Analyst Ratings - Baird analyst Eric Coldwell maintained an Outperform rating and raised the price target from $191 to $194 [7] - Evercore ISI Group analyst Elizabeth Anderson maintained an In-Line rating and increased the price target from $175 to $180 [7] - Barclays analyst Stephanie Davis maintained an Equal-Weight rating and raised the price target from $175 to $185 [7] - Truist Securities analyst David Macdonald maintained a Hold rating and increased the price target from $182 to $190 [7]